The role of kidney injury biomarkers in COVID-19

Lianjiu Su; Jiahao Zhang; Zhiyong Peng

doi:10.1080/0886022X.2022.2107544

The role of kidney injury biomarkers in COVID-19

Ren Fail. 2022 Dec;44(1):1280-1288. doi: 10.1080/0886022X.2022.2107544.

Authors

Lianjiu Su^{1

2}, Jiahao Zhang¹, Zhiyong Peng^{1

3}

Affiliations

¹ Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
² Department of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
³ Department of Critical Care Medicine, Center of Critical Care Nephrology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Abstract

The coronavirus disease-2019 (COVID-19) outbreak has been declared a global pandemic. COVID-19-associated acute kidney injury (COVID-19 AKI) is related to a high mortality rate and serves as an independent risk factor for hospital death in patients with COVID-19. Early diagnosis would allow for earlier intervention and potentially improve patient outcomes. The goal of early identification of AKI has been the primary impetus for AKI biomarker research, and several kidney injury biomarkers have been demonstrated to be beneficial in predicting COVID-19 AKI as well as disease progression in COVID-19. Furthermore, such data provide valuable insights into the molecular mechanisms underlying this complex and unique disease and serve as a molecular phenotyping tool that could be utilized to direct clinical intervention. This review focuses on a number of kidney injury biomarkers, such as CysC, NAGAL, KIM-1, L-FABP, IL-18, suPAR, and [TIMP-2] • [IGFBP7], which have been widely studied in common clinical settings, such as sepsis, cardiac surgery, and contrast-induced AKI. We explore the role of kidney injury biomarkers in COVID-19 and discuss what remains to be learned.

Keywords: Acute kidney injury; COVID-19; biomarker.

Publication types

Review

MeSH terms

Acute Kidney Injury* / diagnosis
Acute Kidney Injury* / etiology
Biomarkers
COVID-19* / complications
Humans
Insulin-Like Growth Factor Binding Proteins
Kidney
Predictive Value of Tests

Substances

Biomarkers
Insulin-Like Growth Factor Binding Proteins

Grants and funding

This work was supported by the National Natural Science Foundation. [grant number 81772046], [grant number 81971816] to ZP, [grant number 82102298] to LS; Innovation Cultivation Foundation of Wuhan University/Zhongnan Hospital [grant number 413000345/CXPY2020017] to LS; and Research Project Foundation of Zhongnan Hospital [grant number ZNYB2020013] to LS.